Females with heterozygous COL4A5 variants are not only asymptomatic carriers of X-linked Alport syndrome but also face an increased risk of CKD, early- or late-onset ESRD, and extrarenal manifestations. This evidence concerns the gene COL4A5 and Alport syndrome.